Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)

Alison J Moskowitz, Robert N Stuver, Steven M Horwitz

Blood blood.2023021789.

https://doi.org/10.1182/blood.2023021789

Published: 2024

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Blood (2022) 140 (Supplement 1): 1756–1758.

https://doi.org/10.1182/blood-2022-156382

Published: 2022

Journal Articles

Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience

William T. Johnson, Zachary D. Epstein-Peterson, Nivetha Ganesan, Tiffany Chang, Natasha Galasso, Robert Stuver, Niloufer Khan, Gilles Salles, Alison J. Moskowitz, Santosha Vardhana, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 3704–3706.

https://doi.org/10.1182/blood-2022-168063

Published: 2022

Journal Articles

Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Blood (2022) 140 (Supplement 1): 9380–9382.

https://doi.org/10.1182/blood-2022-156383

Published: 2022

Journal Articles

Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21 st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant

Robert Stuver, Zachary D. Epstein-Peterson, William T. Johnson, Niloufer Khan, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Alison J. Moskowitz, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 3671–3672.

https://doi.org/10.1182/blood-2022-156384

Published: 2022

Journal Articles

Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling

Robert Stuver, Harleigh Haynie, Zachary D. Epstein-Peterson, William T. Johnson, Niloufer Khan, Anita Mazloom, Alison J. Moskowitz, Esther Drill, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 3669–3670.

https://doi.org/10.1182/blood-2022-167608

Published: 2022

Journal Articles

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 9286–9288.

https://doi.org/10.1182/blood-2022-160206

Published: 2022

Journal Articles

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Blood (2022) 140 (Supplement 1): 9251–9253.

https://doi.org/10.1182/blood-2022-158783

Published: 2022

Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Blood (2021) 138 (26): 2828–2837.

https://doi.org/10.1182/blood.2021013379

Published: 2021

Includes: Supplemental data

Journal Articles

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Blood (2021) 138 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2021-153171

Published: 2021

Journal Articles

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Neha Mehta-Shah, Eric D Jacobsen, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, Amanda F. Cashen, Armin Ghobadi, Beth Reagan, Anne Fischer, Alison J. Moskowitz, Fei Wan, Austin Jacobsen, Meredith Olson, Edgar Vigil, Natalie Hill, Karina Elias, Ying Huang, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2021-148768

Published: 2021

Journal Articles

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Blood (2021) 138 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2021-154226

Published: 2021

Journal Articles

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

Beatriz Wills, Laure Michaud, Heiko Schöder, Nivetha Ganesan, Craig H. Moskowitz, David J. Straus, Lorenzo Falchi, Matthew J. Matasar, Andrew D. Zelenetz, Erel Joffe, Gottfried von Keudell, Connie Lee Batlevi, Audrey Hamilton, Philip C Caron, Ariela Noy, Gilles Salles, Alison J. Moskowitz

Blood (2021) 138 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2021-153383

Published: 2021

Journal Articles

TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy

William T. Johnson, Nivetha Ganesan, Zachary D. Epstein-Peterson, Catherine Maccaro, Natasha Galasso, Craig S. Sauter, Rachel Neuman, Niloufer Khan, Alison J. Moskowitz, Ahmet Dogan, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2021-151779

Published: 2021

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood (2021) 138 (Supplement 1): 879.

https://doi.org/10.1182/blood-2021-147810

Published: 2021

Journal Articles

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Blood (2021) 138 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2021-151994

Published: 2021

Journal Articles

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2021-147527

Published: 2021

Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera

Blood (2021) 138 (6): 427–438.

https://doi.org/10.1182/blood.2020009178

Published: 2021

Includes: Supplemental data

NARROW

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience

Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21 st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant

Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only